furosemide has been researched along with 2019 Novel Coronavirus Disease in 12 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " She was treated because of low left ventricular ejection fraction and impression of postpartum cardiomyopathy, and her severe dyspnea improved by intravenous furosemide." | 4.02 | Severe acute respiratory syndrome coronavirus-2- or pregnancy-related cardiomyopathy, a differential to be considered in the current pandemic: a case report. ( Hajizadeh, R; Kavandi, H; Khademolhosseini, S; Nejadrahim, R, 2021) |
| "Furosemide is a "repurpose-able" small molecule therapeutics, that is safe, easily synthesized, handled, and stored, and is available in reasonable quantities worldwide." | 2.66 | Is Inhaled Furosemide a Potential Therapeutic for COVID-19? ( Barden, C; Brennecke, A; Doyle, LM; Meek, A; Reed, M; Villar, L; Wang, Z; Weaver, DF, 2020) |
| " This patient's case highlights the need of further studies evaluating efficacy of repeated dosing of CCP." | 1.62 | Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient. ( Bloch, EM; Chua, F; Goel, R; Katz, LM; Mirihagalle, N; Parajuli, P; Prakash, V; Saha, D; Shah, A; Sundareshan, V; Tobian, AAR; Waqar, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsumura, Y | 1 |
| Sugiyama, T | 1 |
| Kondo, N | 1 |
| Miyahara, M | 1 |
| Hanaoka, N | 1 |
| Nagashima, H | 1 |
| Kasahara, Y | 1 |
| Fujiyoshi, N | 1 |
| Inada, A | 1 |
| Inaba, S | 1 |
| Kondo, M | 1 |
| Gempei, M | 1 |
| Watanabe, K | 1 |
| Yoshida, M | 1 |
| Tagui, N | 1 |
| Fukao, S | 1 |
| Sugaya, K | 1 |
| Takase, H | 1 |
| Loucera, C | 1 |
| Carmona, R | 1 |
| Esteban-Medina, M | 1 |
| Bostelmann, G | 1 |
| Muñoyerro-Muñiz, D | 1 |
| Villegas, R | 1 |
| Peña-Chilet, M | 1 |
| Dopazo, J | 1 |
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Brennecke, A | 1 |
| Villar, L | 1 |
| Wang, Z | 1 |
| Doyle, LM | 1 |
| Meek, A | 1 |
| Reed, M | 1 |
| Barden, C | 1 |
| Weaver, DF | 1 |
| Piperata, A | 1 |
| Bottio, T | 1 |
| Gerosa, G | 1 |
| Chitsazan, M | 2 |
| Amin, A | 1 |
| Ziaie, N | 1 |
| Amri Maleh, P | 1 |
| Pouraliakbar, H | 1 |
| Von Haehling, S | 1 |
| Casas-Aparicio, GA | 1 |
| León-Rodríguez, I | 1 |
| Alvarado-de la Barrera, C | 1 |
| González-Navarro, M | 1 |
| Peralta-Prado, AB | 1 |
| Luna-Villalobos, Y | 1 |
| Velasco-Morales, A | 1 |
| Calderón-Dávila, N | 1 |
| Ormsby, CE | 1 |
| Ávila-Ríos, S | 1 |
| Kevorkian, JP | 1 |
| Lopes, A | 1 |
| Sène, D | 1 |
| Riveline, JP | 1 |
| Vandiedonck, C | 1 |
| Féron, F | 1 |
| Nassarmadji, K | 1 |
| Mouly, S | 1 |
| Mauvais-Jarvis, F | 1 |
| Gautier, JF | 1 |
| Mégarbane, B | 1 |
| Nejadrahim, R | 1 |
| Khademolhosseini, S | 1 |
| Kavandi, H | 1 |
| Hajizadeh, R | 1 |
| Mirihagalle, N | 1 |
| Parajuli, P | 1 |
| Sundareshan, V | 1 |
| Saha, D | 1 |
| Shah, A | 1 |
| Chua, F | 1 |
| Waqar, S | 1 |
| Prakash, V | 1 |
| Tobian, AAR | 1 |
| Bloch, EM | 1 |
| Katz, LM | 1 |
| Goel, R | 1 |
| Ahmed, FZ | 1 |
| Taylor, JK | 1 |
| John, AV | 1 |
| Khan, MA | 1 |
| Zaidi, AM | 1 |
| Mamas, MA | 1 |
| Motwani, M | 1 |
| Cunnington, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study[NCT04588792] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2021-04-16 | Terminated (stopped due to Lack of recruitment due to decline in critically ill Covid-19 patients) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for furosemide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
Topics: Administration, Inhalation; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Fur | 2020 |
11 other studies available for furosemide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Fluid restriction management in the treatment of COVID-19: a single-center observational study.
Topics: Anticoagulants; COVID-19; Female; Furosemide; Humans; Male; Oxygen; Respiration, Artificial; SARS-Co | 2022 |
Y-site Injection Physical Compatibility of Remdesivir with Select Intravenous Drugs Used in Palliative Care and for Treating Coronavirus Disease 2019.
Topics: COVID-19; COVID-19 Drug Treatment; Furosemide; Humans; Infusions, Intravenous; Morphine Derivatives; | 2023 |
Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments.
Topics: COVID-19; Databases, Factual; Furosemide; Humans; Retrospective Studies; Treatment Outcome | 2023 |
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
COVID-19 infection in left ventricular assist device patients.
Topics: Aged; Cardiotonic Agents; COVID-19; Dobutamine; Furosemide; Heart Failure; Heart-Assist Devices; Hum | 2020 |
Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients.
Topics: COVID-19; Diuretics; Furosemide; Heart Failure; Humans; Male; Middle Aged; Stroke Volume | 2021 |
Acute kidney injury in patients with severe COVID-19 in Mexico.
Topics: Acute Kidney Injury; Biomarkers; COVID-19; Female; Furosemide; Humans; Inflammation; Kaplan-Meier Es | 2021 |
Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study.
Topics: Adrenal Cortex Hormones; Anticoagulants; Aspirin; Cohort Studies; Colchicine; COVID-19; Furosemide; | 2021 |
Severe acute respiratory syndrome coronavirus-2- or pregnancy-related cardiomyopathy, a differential to be considered in the current pandemic: a case report.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Cardiomyopathies; Cesarean Section; Co | 2021 |
Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient.
Topics: Anti-Bacterial Agents; Combined Modality Therapy; COVID-19; COVID-19 Serotherapy; Diabetes Mellitus, | 2021 |
Ambulatory intravenous furosemide for decompensated heart failure: safe, feasible, and effective.
Topics: COVID-19; Furosemide; Heart Failure; Humans; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2021 |